• 1
    Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995; 273: 811817
  • 2
    Stenman UH, Hakama M, Knekt P, Aromaa A, Teppo L, Leinonen J. Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. Lancet 1994; 344: 15948
  • 3
    Parkes C, Wald NJ, Murphy P et al. Prospective observational study to assess value of prostate specific antigen as screening test for prostate cancer. Br Med J 1995; 311: 13403
  • 4
    Koning de HJ, Auvinen A, Berenguer Sanchez A et al. Large-scale randomized prostate cancer screening trials; program performances in the ERSPC- and PLCO-trials (European Randomized Screening for Prostate Cancer and Prostate, Lung, Colorectal and Ovary cancer trials) 2001
  • 5
    Oliver SE, Gunnell D, Donovan JL. Comparison of trends in prostate-cancer mortality in England and Wales and the USA. Lancet 2000; 355: 17889DOI: 10.1016/s0140-6736(00)02269-8
  • 6
    Visser O, Coebergh JWW, Schouten LJ, Van Dijck JAAM eds. Incidence of Cancer in the Netherlands 1997. Utrecht: Vereniging Van Integrale Kankercentral, 2001
  • 7
    Greenlee RT, Hill-Harmon MB, Thun M. Cancer statistics. CA Cancer J Clin 2001; 51: 1536
  • 8
    Bartsch G, Horninger W, Klocker H et al. Decrease in prostate cancer mortality following introduction of prostate specific antigen (PSA) screening in the federal state of Tyrol, Austria. J Urol 2000; 163(Suppl. 4): 88, A387
  • 9
    Labrie F, Candas B, Dupont A et al. Screening decreases prostate cancer death. first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 1999; 38: 8391
  • 10
    Alexander FE. Screening decreases prostate cancer death. First analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 1999; 40: 1356DOI: 10.1002/(sici)1097-0045(19990701)40:2<135::aid-pros11>;2-y
  • 11
    Boer R & Schröder FH. Quebec randomized controlled trial on prostate cancer screening shows no evidence for mortality reduction [letter]. Prostate 1999; 40: 1304
  • 12
    CDC Website. 2001
  • 13
    Hankey BF, Feuer EJ, Clegg LX et al. Cancer Surveillance Series: Interpreting trends in prostate cancer – Part I. Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 1999; 91: 101724
  • 14
    Etzioni R, Legler JM, Feuer EJ, Merrill RM, Cronin KA, Hankey BF. Cancer surveillance series: interpreting trends in prostate cancer – part III. Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. J Natl Cancer Inst 1999; 91: 10339DOI: 10.1093/jnci/91.12.1033
  • 15
    Stanford JL, Stephenson RA, Coyle LM et al. Prostate cancer trends, 1973–95. SEER Program National Cancer Institute. National Cancer Institute Monograph 1998 ( 1998
  • 16
    Damhuis RAM & Kirkels WJ and the EUROCARE Working Group. Improvement in survival of patients with cancer of the kidney in Europe. Eur J Cancer 1999; 34: 22325
  • 17
    Madalinska JB, Essink-Bot ML, De Koning HJ, Kirkels WJ, Van Der Maas PJ, Schröder FH. Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol 2001; 19: 161228
  • 18
    Litwin MS, Fitzpatrick JM, Fossa SD, Newling DWW. Defining an international research agenda for quality of life in men with prostate cancer. Prostate 1999; 41: 5867
  • 19
    Beemsterboer PM, De Koning HJ, Birnie E, Van Der Maas PJ, Schröder FH. Advanced prostate cancer. Course, care, and cost implications. Prostate 1999; 40: 97104DOI: 10.1002/(sici)1097-0045(19990701)40:2<97::aid-pros5>;2-a
  • 20
    Carter HB, Pearson JD, Metter EJ et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992; 267: 221520
  • 21
    Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. Long-term survival among men with conservatively treated localized prostate cancer. JAMA 1995; 274: 62631
  • 22
    Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55–74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998; 280: 97580
  • 23
    Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271: 36874
  • 24
    Chan ECY & Sulmasy DP. What should men know about prostate-specific antigen screening before giving informed consent? Am J Med 1998; 105: 26674
  • 25
    Catalona WJ, Miller DR, Kavoussi LR. Intermediate-term survival results in clinically understaged prostate cancer patients following radical prostatectomy. J Urol 1988; 140: 5403
  • 26
    Kranse R, Beemsterboer P, Rietbergen J, Habbema D, Hugosson J, Schröder FH. Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam region). Prostate 1999; 39: 31622DOI: 10.1002/(sici)1097-0045(19990601)39:4<316::aid-pros14>;2-o
  • 27
    Hoedemaeker RF, Rietbergen JB, Kranse R, Van Der Kwast TH, Schröder FH. Comparison of pathologic characteristics of T1c and non-T1c cancers detected in a population-based screening study, the European Randomized Study of Screening for Prostate Cancer. World J Urol 1997; 15: 33945
  • 28
    Schröder FH, Van Der Maas P, Beemsterboer P et al. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 1998; 90: 181723DOI: 10.1093/jnci/90.23.1817
  • 29
    Schröder FH, Van Der Cruijsen-Koeter I, De Koning HJ, Vis AN, Hoedemaeker RF, Kranse R. Prostate cancer detection at low prostate specific antigen. J Urol 2000; 163: 80612
  • 30
    Schröder FH, Roobol-Bouts M, Vis AN, Van Der Kwast T, Kranse R. Prostate-specific antigen-based early detection of prostate cancer – validation of screening without rectal examination. Urology 2001; 57: 8390
  • 31
    Eskew LA, Bare RL, McCullough DL. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 1997; 157: 199202
  • 32
    Koppie TM & Carroll PR. Watchful waiting for prostate cancer: it's not for everyone. AUA News 2001; Jan/Feb: 14
  • 33
    Davidson PJT, Hop W, Kurth KH et al. Progression in untreated carcinoma of the prostate metastatic to regional lymph nodes (stage T0–4,N1–3,Mo,D1). J Urol 1995; 154: 211822
  • 34
    Klotz L, Choo R, DeBoer G et al. PSA doubling time of prostate carcinoma managed with watchful observation alone. J Urol 2000; 163(Suppl. 4): 58, A251
  • 35
    American Urological Society. Executive Committee Report. Baltimore: American Urological Association, 1992
  • 36
    Pruthi RS, Johnstone I, Tu IP, Stamey TA. Prostate-specific antigen doubling times in patients who have failed radical prostatectomy. correlation with histologic characteristics of the primary cancer. Urology 1997; 49: 73742
  • 37
    Smith RA, Von Eschenbach AC, Wender A et al. American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. CA Cancer J Clin 2001; 51: 3875
  • 38
    American Medical Association. AMA Report 9 of the Council on Scientific Affairs. Screening and Early Detection of Prostate Cancer. CSA Report 9-a-00. 2000: 122
  • 39
    Ferrini R & Woolf SH. Screening for prostate cancer in American men. American College of Preventive Medicine Practice Policy Statement. American Cancer Society Prostate Cancer Screening Guideline Conference 2000 Update, May 4–6, 2000. Atlanta 2000
  • 40
    American College of Physicians. Clinical guidelines: Part III. Screening for prostate cancer. Ann Intern Med 1997; 126: 4804
  • 41
    Advisory Committee on Cancer Prevention. Recommendations on cancer screening in the European Union. Eur J Cancer 2000; 36: 14738

F.H. Schröder, MD, Professor.

M.F. Wildhagen.


European Randomised Study of Screening for Prostate Cancer


quality-of-life adjusted gain in years


quality of life


positive predictive value


PSA doubling time.